Zacharoulis, S., Szalontay, L., CreveCoeur, T., Neira, J., Higgins, D., Englander, Z., Spinazzi, E., Sethi, C., Canoll, P., Garvin, J., Zylber, R., Damment, S., Zamoryakhin, D., Maddocks, A., Feldstein, N., & Bruce, J. (2022). DDEL-07. A Phase I study examining the feasibility of intermittent convection-enhanced delivery (CED) of MTX110 for the treatment of children with newly diagnosed diffuse midline gliomas (DMGs). Neuro-Oncology, 24(Supplement_1), i35–i35. https://doi.org/10.1093/neuonc/noac079.128

Minns, H. E., Padilla, O., Wei, H.-J., Webster-Carrion, A., Tazhibi, M., McQuillan, N., Zhang, X., Yeh, R., Zhang, Z., Szalontay, L., Pavisic, J., Garty, G., Garvin, J., Zacharoulis, S., Canoll, P., Vanpouille-Box, C. I., Menon, V., Olah, M., Rabadan, R., … Gartrell, R. D. (2022). DIPG-45. Radiation induces a robust interferon response in Diffuse Midline Glioma (DMG), improving the potential for combination immunotherapy. Neuro-Oncology, 24(Supplement_1), i28–i29. https://doi.org/10.1093/neuonc/noac079.102

Fernández, E. C., Wang, J., Griffin, A., Minns, H., Wei, H.-J., Zhang, X., Szalontay, L., Mundi, P., Wu, C.-C., Gartrell, R., Zacharoulis, S., Califano, A., & Pavisic, J. (2022). DIPG-57. A systems biology approach to defining and targeting master regulator dependencies from bulk and single-Cell RNA-seq in diffuse midline glioma (DMG). Neuro-Oncology, 24(Supplement_1), i31–i32. https://doi.org/10.1093/neuonc/noac079.114

Genecin, I., Fullwood, D., Moisander-Joyce, H., Padilla, O., Minns, H., Garvin, J., Szalontay, L., Wu, C.-C., Kahn, J., & Gartrell, R. D. (2022). EPID-07. Outcome disparities in children, adolescents and young adults with medulloblastoma: A population-based analysis. Neuro-Oncology, 24(Supplement_1), i48–i48. https://doi.org/10.1093/neuonc/noac079.175

Webster Carrion, A., Wei, H.-J., McQuillan, N., Tazhibi, M., Kokossis, D., Berg, X., Minns, H., Zhang, X., Zhang, Z., Wang, J., Fernandez, E. C., Jan, C.-I., Padilla, O., Gartrell, R. D., Becher, O., Jr, J. H. G., Pavisic, J., Szalontay, L., Konofagou, E. E., … Wu, C.-C. (2022). MODL-24. Focused ultrasound-mediated blood-brain barrier opening and panobinostat in a thalamic syngeneic murine DMG model is feasible and safe. Neuro-Oncology, 24(Supplement_1), i174–i174. https://doi.org/10.1093/neuonc/noac079.647

McQuillan, N., Tazhibi, M., Wei, H.-J., Pouliopoulos, A., Bendau, E., Carrion, A. W., Berg, A., Kokossis, D., Zhang, X., Zhang, Z., Englander, Z., Yoh, N., Jan, C.-I., Gartrell, R. D., Garvin, J., Szalontay, L., Konofagou, E., Zacharoulis, S., & Wu, C.-C. (2022). MODL-25. Radiation and focused ultrasound–mediated blood–brain barrier opening for DMG: safety and feasibility of combinatorial therapy. Neuro-Oncology, 24(Supplement_1), i174–i174. https://doi.org/10.1093/neuonc/noac079.648

Hill, K., Miller, A. M., Li, B. K., Bouvier, N., Li, S., Alano, T., Doe-Tetteh, S., Huereca, C., DiNapoli, S., Lee, A., Szalontay, L., Riviere-Cazaux, C., Burns, T. C., Haque, S., Bale, T., Benhamida, J., Dogan, S., Vanderbilt, C., Ross, D., … Karajannis, M. (2022). PATH-16. Noninvasive diagnosis of gliomas through CSF cfDNA sequencing in pediatric and adolescent and young adult (AYA) patients. Neuro-Oncology, 24(Supplement_1), i162–i162. https://doi.org/10.1093/neuonc/noac079.600

Trudeau, T., Prince, E., Chatain, O., Chee, K., Jackson, E., Limbrick, D., Naftel, R., Feldstein, N., Grant, G., Ginn, K., Niazi, T., Smith, A., Kilburn, L., Chern, J., Drapeau, A., Lam, S., Johnston, J., Dudley, R., Staulcup, S., & Hankinson, T. (2022). RARE-24. The use of novelin vitro models to study adamantinomatous craniopharyngioma disease biology and drug response. Neuro-Oncology, 24(Supplement_1), i15–i15. https://doi.org/10.1093/neuonc/noac079.049

Mohile, N. A., Messersmith, H., Gatson, N. T. N., Hottinger, A. F., Lassman, A. B., Morton, J., Ney, D., Nghiemphu, P. L., Olar, A., Olson, J., Perry, J., Portnow, J., Schiff, D., Shannon, A., Shih, H. A., Strowd, R., van den Bent, M., Ziu, M., & Blakeley, J. (2021). Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. Neuro-Oncology, 24(3), 358–383. https://doi.org/10.1093/neuonc/noab279

Petridis, P. D., Horenstein, C. I., Pereira, B., Wu, P. B., Samanamud, J., Marie, T., Boyett, D., Sudhakar, T. D., Sheth, S. A., McKhann, G. M., Sisti, M. B., Bruce, J. N., Canoll, P., & Grinband, J. (2021). BOLD asynchrony elucidates tumor burden in IDH-mutated gliomas. Neuro-Oncology, 24(1), 78–87. https://doi.org/10.1093/neuonc/noab154